Cite
HARVARD Citation
Tinker, A. et al. (n.d.). 2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study. International journal of gynecological cancer. p. A130. [Online].